Description

Rapimig (zolmitriptan) dispersible tablets 5 mg. №2

Ingredients

Each dispersible tablet contains 5 mg of zolmitriptan.

Dosage

The recommended dosage is one tablet as needed, not exceeding 10 mg in 24 hours.

Indications

Rapimig is indicated for the acute treatment of migraine attacks with or without aura.

Contraindications

Do not use Rapimig if you have uncontrolled hypertension, ischemic heart disease, or severe hepatic impairment.

Directions

Place the tablet on the tongue, where it will disintegrate in seconds, then swallow with saliva. No water is needed.

Scientific Evidence

Zolmitriptan, the active ingredient in Rapimig, is a selective serotonin receptor agonist that works by constricting blood vessels in the brain, reducing inflammation, and blocking pain signals. Clinical trials have shown zolmitriptan to be effective in relieving migraine symptoms, including pain, nausea, and sensitivity to light and sound.

A study published in the Journal of Headache and Pain demonstrated that zolmitriptan dispersible tablets provided rapid and sustained relief of migraine pain compared to a placebo, with a significant number of patients experiencing pain relief within 2 hours of taking the medication.

Additional Information

• Rapimig should not be used prophylactically to prevent migraines.
• Common side effects may include dizziness, drowsiness, and dry mouth.
• If migraine symptoms persist or worsen after taking Rapimig, seek medical advice.